At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 86 enrolled
Drug / intervention
Eribulin Mesylate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC)
In Brief
A Phase 2 clinical trial evaluating Eribulin Mesylate and Laboratory Biomarker Analysis for Recurrent Breast Carcinoma and Stage IV Breast Cancer. Completed, enrolled 86 participants across 12 sites.
Detailed Summary
This phase II trial studies how well eribulin mesylate works in treating patients with previously treated breast cancer that has spread to other places in the body. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Breast Carcinoma, Stage IV Breast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartJan 2014
Primary CompletionMay 2019
TodayJul 2026
First PostedJul 25, 2013
Enrollment StartJan 8, 2014
Primary CompletionMay 4, 2019
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 12.9 years ago
Interventions
Eribulin Mesylatedrug
Given IV
Laboratory Biomarker Analysisother
Correlative studies